HOME >> MEDICINE >> NEWS
Drug-eluting stents adopted quickly, with early disparities

DURHAM, N.C. -- In the first comprehensive survey of its kind, Duke Clinical Research Institute researchers have documented that while the adoption of new drug-eluting stents has been rapid, their use has not been universally uniform among patients receiving them.

Furthermore, the researchers said, about one-third of the new stents were placed in patients with clinical characteristics for which such stent use has not yet been approved by the Food and Drug Administration (FDA). However, the researchers said that their finding of a high rate of "off-label" usage should be seen more as an impetus for further clinical trials rather than an immediate safety issue, since cardiologists have been placing traditional stents for more than 10 years and are comfortable with the procedure.

Stents are tiny mesh tubes that are inserted into the site of a blockage in a coronary artery that has been opened during balloon angioplasty. However, a principal complication of the procedure has been the high rate of treated arteries becoming blocked again, a process known as restenosis.

In an attempt to improve stents to keep treated arteries open, stent manufacturers coated them with a chemotherapeutic agent that limits the formation of scar tissue inside the artery. So far, clinical trials have shown that these new stents can reduce the restenosis rate to single digits from the 20 to 30 percent rate of the older stents. The first drug-eluting stent received FDA approval in April, 2003.

"Drug-eluting stents are truly breakthrough products in treating coronary artery disease, and in our analysis of the early trends of the their use, we found disparities in terms of age, race and socio-economic factors," said Duke cardiologist Sunil Rao, M.D., who presented the results of the Duke analysis Nov. 10, 2004, at the American Heart Association's annual scientific sessions in New Orleans.

"We also found that the rate of increased usage for off-label use was
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
10-Nov-2004


Page: 1 2 3

Related medicine news :

1. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis
2. Study says rare allergic reactions to drug-eluting stents may raise risk for heart attack
3. Coronary stents do not improve long-term survival
4. Early reports of thrombosis after insertion of drug-eluting stents
5. Drug-coated stents effective in real world patients
6. Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
7. Stanford computer model shows bypass surgery more cost-effective than stents
8. Research explores why some internationally adopted children excel while others struggle
9. Mandel School researchers receive $700,000 for study to promote well-being of adopted children
10. Sandia-developed foam likely would stop SARS virus quickly, Sandia/Kansas State team shows
11. New marker for early diagnosis of kidney failure identified

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drug eluting stents adopted quickly with early disparities

(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... Eugene, OR (PRWEB) November 22, 2014 The ... addition of Roy Baroff to its team of ... lawyer, mediator, soccer player, coach, and referee. He has over ... North Carolina and beyond. , “I'm very excited to connect ... experience and sports related interests to a program with a ...
(Date:11/22/2014)... Columbus, OH (PRWEB) November 22, 2014 ... trials for AndroGel side-effects lawsuits have been scheduled ... District Court, Northern District of Illinois. U.S. District Judge ... litigation, issued a Case Management Order (CMO) on November ... as deadlines for attorneys to submit documents and other ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... outcomes are better when patients are treated in an ambulance ... drugs, German researchers report. The sooner patients get the ... the outcome after a stroke, the researchers noted. For the ... first hour after stroke symptoms start, the researchers said. ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
(Date:11/22/2014)... 21, 2014 Many power shifts are ... influence of patients in the biopharmaceutical market is ... more than ever, understanding how to effectively acquire, ... is essential. According to recent ... companies spent about two-thirds of their patient-focused dollars ...
(Date:11/21/2014)... 2014 In September 2014, the staff at ... a new product development plan that started with the ... lab coat , aptly named "Vera G.," after ... the world. The new women,s designer lab coat is ... sleek envelope collar, vertical princess and high waist seaming, ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
Cached News: